Molecular profiling of bladder cancer using cDNA microarrays: Defining histogenesis and biological phenotypes

Cancer Research

Volumn 62, Issue 23, 2002, Pages 6973-6980

  Sanchez Carbayo, Marta ^a   Socci, Nicholas D ^b   Charytonowicz, Elizabeth ^a   Lu, Minglan ^a   Prystowsky, Michael ^b   Childs, Geoffrey ^b   Cordon Cardo, Carlos ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; KERATIN; KERATIN 10; MOESIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; ZYXIN;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER STAGING; CELL ADHESION; CELL CYCLE; CONTROLLED STUDY; DEREGULATION; DNA MICROARRAY; EPITHELIUM CELL; EXPRESSED SEQUENCE TAG; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; HISTOGENESIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; VALIDATION PROCESS;

CADHERINS; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; CAVEOLIN 1; CAVEOLINS; CELL DIFFERENTIATION; CLUSTER ANALYSIS; CYTOSKELETAL PROTEINS; GENE EXPRESSION PROFILING; GLYCOPROTEINS; HUMANS; KERATIN-10; KERATINS; METALLOPROTEINS; MICROFILAMENT PROTEINS; MONTE CARLO METHOD; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0036897242     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Reuter, V. E., and Melamed, M. R. The lower urinary tract. In: S. S. Sternberg (ed.), Diagnostic Surgical Pathology, pp. 1355-1392. New York: Raven Press, 1989.
2. Zhang, Z-F., and Steineck, G. Epidemiology and etiology of bladder cancer. In: D. Raghavan, H. I. Scher, S. A. Leibel, and P. Lange (eds.), Principles and Practice of Genitourinary Oncology, pp. 215-222. Philadelphia: J. B. Lippincott Company, 1996.
3. Mostofi, F. K., and Sesterhenn, I. A. Pathology of epithelial tumors and carcinoma in situ of bladder. Prog. Clin. Biol. Res., 62: 55-74, 1984.
4. Dalbagni, G., Presti, J., Reuter, V., Fair, W. R., and Cordon-Cardo, C, Genetic alterations in bladder cancer. Lancet, 324: 469-471, 1993.
5. Cordon-Cardo, C., Cote, R. J., and Sauter, G. Genetic and molecular markers of urothelial premalignancy and malignancy. Scand. J. Urol. Nephrol. Suppl., 205: 82-93, 2000.
6. Reznikoff, C. A., Belair, C., Savelieva, E., Zhai, Y., Pfeifer, K., Yeager, T., Thompson, K. J., DeVries, S., Bindley, C., and Newton, M. A. Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes Dev., 8: 2227-2240, 1994.
7. Markl, I. D., and Jones, P. A. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res., 58: 5348-5353, 1998.
8. Cordon-Cardo, C., Zhang, Z. F., Dalbagni, G., Drobnjak, M., Charytonowicz, E., Hu, S. X., Xu, H. J., Reuter, V. E., and Benedict, W. F. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res., 57: 1217-1221, 1997.
9. Kallioniemi, A., Kallioniemi, O. P., Citro, G., Sauter, G., DeVries, S., Kerschmann, R., Caroll, P., and Waldman, F. Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes Cancer, 12: 213-219, 1995.
10. Giroldi, L. A., Bringuier, P. P., Shimazui, T., Jansen, K., and Schalken, J. A. Changes in cadherin-catenin complexes in the progression of human bladder carcinoma. Int. J. Cancer, 82: 70-76, 1999.
11. Popov, Z., Gil-Diez de Medina, S., Lefrere-Belda, M. A., Hoznek, A., Bastuji-Garin, S., Abbou, C. C., Thiery, J. P., Radvanyi, F., and Chopin, D. K. Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information. Br. J. Cancer, 83: 209-214, 2000.
12. El-Rifai, W., Kamel, D., Larramendy, M. L., Shoman, S., Gad, Y., Baithun, S., El-Awady, M., Eissa, S., Khaled, H., Soloneski, S., Sheaff, M., and Knuutila, S. DNA copy number changes in Schistosoma-associated and non-Schistosoma-associated bladder cancer. Am. J. Pathol., 156: 871-878, 2000.
13. Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., Bloomfield, C. D., and Lander, E. S. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science (Wash. DC), 286: 531-537, 1999.
14. Nielsen, T. O., West, R. B., Linn, S. C., Alter, O., Knowling, M. A., O'Connell, J. X., Zhu, S., Fero, M., Sherlock, G., Pollack, J. R., Brown, P. O., Botstein, D., and van de Rijn, M. Molecular characterisation of soft tissue tumours: A gene expression study. Lancet, 359: 1301-1307, 2002.
15. Cheung, V. G., Morley, M., Aguilar, F., Massimi, A., Kucherlapati, R., and Childs, G. Making and reading microarrays. Nat. Genet., 21 (Suppl.): 15-19, 1999.
16. Stears, R. L., Getts, R. C., and Gullans, S. R. A novel, sensitive detection system for high-density microarrays using dendrimer technology. Physiol. Genomics, 3: 93-99, 2000.
17. Eisen, M. B., Spellman, P. T., Brown, P. O., and Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA, 95: 14863-14868, 1998.
18. Dudoit, S. Statistical Methods for Identifying Differentially Expressed Genes in Replicated cDNA Microarray Experiments. University of California Berkeley Department of Statistics Technical Report #578. http://www.stat.berkeley.edu/tech-reports/578. ps. z, 2000.
19. Hoos, A., Urist, M. J., Stojadinovic, A., Mastorides, S., Dudas, M. E., Leung, D. H., Kuo, D., Brennan, M. F., Lewis, J. J., and Cordon-Cardo, C. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am. J. Pathol., 158: 1245-1251, 2001.
20. American Joint Committee on Cancer. Staging of cancer at genitourinary sites, In: American Joint Committee on Cancer: Manual for Staging of Cancer, 3rd Ed., pp. 194-195. Philadelphia: J. B. Lippincott Co., 1988.
21. Mostofi,F. K. Histological Typing of Urinary Bladder Tumors. Geneva: WHO. 1973.
22. McShane, L. M., Aamodt, R., Cordon-Cardo, C., Cote, R., Faraggi, D., Fradet, Y., Grossman, H. B., Peng, A., Taube, S. E., and Waldman, F. M. Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin. Cancer Res., 6: 1854-1864. 2000.
23. Tudor, G., and Koch, G. G. Review of nonparametric methods for the analysis of crossover studies. Stat. Methods Med. Res., 3: 345-381. 1994.
24. Fleming, T. R., and Lin, D. Y. Survival analysis in clinical trials: Past developments and future directions. Biometrics. 56: 971-983. 2000.
25. Kaplan, E., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat., 53: 457-481, 1958.
26. Wu, R. L., Osman, I., Wu, X. R., Lu, M. L., Zhang, Z. F., Liang, F. X., Hamza, R., Scher, H., Cordon-Cardo, C., and Sun, T. T. Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: Alternative pathways of bladder epithelial differentiation and tumor formation. Cancer Res., 58: 1291-1297, 1998.
27. Nollet, F., Kools, P., and van Roy, F. Phylogenetic analysis of the cadherin superfamily allows identification of six major subfamilies besides several solitary members. J. Mol. Biol., 299: 551-572. 2000.
28. Wikman, F. P., Lu, M. L., Thykjaer, T., Olesen, S. H., Andersen, L. D., Cordon-Cardo, C., and Omtoft, T. F. Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples. Clin. Chem., 46: 1555-1561, 2000.
29. Ostergaard, M., Rasmussen, H. H., Nielsen, H. V., Vorum, H., Omtoft, T. F., Wolf, H., and Celis, J. E. Proteome profiling of bladder squamous cell carcinomas: Identification of markers that define their degree of differentiation. Cancer Res., 57: 4111-4117, 1997.
30. Fine, S. W. Lisanti, M. P., Galbiati, F., and Li, M. Elevated expression of caveolin-1 in adenocarcinoma of the colon. Am. J. Clin. Pathol., 115: 719-724, 2001.
31. Mellon, J. K., Lunec, J., Wright, C., Home, C. H. W., Kelly, P., and Neal, D. E. ERBB2 in bladder cancer: Molecular biology, correlation with epidermal growth factor receptors and prognostic value. J. Urol., 155: 321-326. 1996.
32. Rajjayabun, P. H., Garg, S., Durkan, G. C., Charlton, R., Robinson, M. C., and Mellon, J. K. Caveolin-1 expression is associated with high-grade bladder cancer. Urology, 58: 811-814, 2001.
33. Kern, S., E., Pietenpol, J. A., Thiagalingam, S., Seymour, A., Kinzler, K. W., and Vogelstein, B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (Wash. DC), 256: 827-830, 1992.
34. Friedlander, P., Haupt, Y., Prives, C., and Oren, M., A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol. Cell. Biol., 16: 4961-4967, 1996
35. Cordon-Cardo, C., Dalbagni, G., Saez, G. T., Oliva, M. R., Zhang, Z. F., Rosai, J., Reuter, V. E., and Pellicer, A. p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns. Int. J. Cancer, 56: 347-353, 1994.
36. Wang, Y., and Gilmore, T. D. LIM domain protein Trip6 has a conserved nuclear export signal, nuclear targeting sequences, and multiple transactivation domains. Biochim. Biophys. Acta, 1538: 260-272, 2001.
37. Martoglio, A. M., Tom, B. D., Starkey, M., Corps, A. N., Charnock-Jones, D. S., and Smith, S. K. Changes in tumorigenesis- and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays. Mol. Med., 6: 750-765, 2000.
38. Ichikawa, T., Masumoto, J., Kaneko. M., Saida, T., Sagara, J., and Taniguchi, S. Moesin and CD44 expression in cutaneous melanocytic turnouts. Br. J. Dermatol., 138: 763-768, 1998.
39. Tokunou, M., Niki, T., Saitoh, Y., Imamura, H., Sakamoto, M., and Hirohashi. S. Altered expression of the ERM proteins in lung adenocarcinoma. Lab. Investig., 80: 1643-1650, 2000.
40. Crawford, A. W., Michelsen, J. W., and Beckerle M. C. An interaction between zyxin and α-actinin. J. Cell Biol., 116: 1381-1393. 1992.
41. Schulze, C., and Firth, J. A. Immunohistochemical localization of adherens junction components in blood-brain barrier microvessels of the rat. J. Cell Sci., 104: 773-782, 1993.
42. Hiscox, S., and Jiang, W. G. Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/13-catenin. J. Cell Sci., 112: 3081-3090. 1999.
43. Shiina, H., Igawa, M., Urakami, S., Shigeno, K., Yoneda, T., Terashima, M., Deguchi, M., Ribeiro-Filho, L., and Dahiya, R. Alterations of β and γ-catenin in N-butyl-N-(-4-hydroxybutyl)nitrosamine-induced murine bladder cancer. Cancer Res., 61: 7101-7109, 2001.
44. Hsu, S. C., Galceran, J., and Grosschedl, R. Modulation of transcr tional regulation by LEF-1 in response to Wnt-1 signaling and association with β-catenin. Mol. Cell. Biol., 118: 4807-4818, 1998.
45. Aberle, H., Bauer, A., Stappert, J., Kispert, A., and Kemier, R. β-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J., 16: 3797-3804. 1997.
46. Saito, T., Oda, Y., Tanaka, K., Matsuda, S., Tamiya, S., Iwamoto, Y., and Tsuneyoshi, M. β-Catenin nuclear expression correlates with cyclin D I overexpression in sporadic desmoid tumors. J. Pathol, 195: 222-228. 2001.
47. Espada, J., Moreno, M. P., Braga, V. M., Rodriguez-Viciana, P., and Cano, A. H-ras activation promotes cytoplasmic accumulation and phosphoinositode 3-OH kinase association of β-catenin in epidermal keratinocytes. J. Cell Biol., 146: 967-980, 1999.
48. Sadot, E., Geiger, B., Oren, M., and Ben-Ze'ev, A. Down-regulation of β-catenin by activated p53. Mol. Cell. Biol., 20: 6768-6781, 2001.